Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement-Reference-Cited by-同舟云学术

Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement

Published:2020-01-29 Issue: Volume:21 Page:
ISSN:1941-5923
Container-title:American Journal of Case Reports
language:en
Short-container-title:Am J Case Rep

Author:

Mociková Heidi¹,Malikova Hana²,Holesta Michal³,Elturki Abdulfattah⁴,Campr Vit⁵,Kozak Tomas¹

Affiliation:

1. Department of Internal Medicine and Hematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

2. Department of Radiology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

3. , , ,

4. Department of Medical Oncology and Hematology, Misurata Cancer Center, Misurata, Libyan Arab Jamahiriya

5. Institute of Pathology and Molecular Medicine, University Hospital Motol, Prague, Czech Republic

Publisher

International Scientific Information, Inc.

Subject

General Medicine

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central nervous system relapse after combination therapy including polatuzumab vedotin in patients with diffuse large B-cell lymphoma;Leukemia Research Reports;2024

2. Cutaneous T-cell lymphoma with CNS involvement: a case series and review of the literature;CNS Oncology;2023-12-01

3. Central Nervous System Relapse in T and NK cell Lymphomas;Current Hematologic Malignancy Reports;2023-08-25

4. Central Nervous System Progression/Relapse in Mature T- and NK-Cell Lymphomas;Cancers;2023-02-01

5. Primary and secondary central nervous system mature T- and NK-cell lymphomas;Seminars in Hematology;2021-04